Metformin in Pulmonary Hypertension in Left Heart Disease

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2020 Sep 25

PMID 32974359

Citations 4

Authors

Vinaya Mulkareddy

Marc A Simon

Affiliations

Soon will be listed here.

Abstract

Metformin is ubiquitously used in the management of Type II Diabetes Mellitus (DMII). Over the years, our growing knowledge of its therapeutic potential has broadened its use to the treatment of infertility in polycystic ovarian syndrome, gestational diabetes, and even obesity. Recently, it has been suggested as a novel therapy in cardiovascular disease (CVD). Given that CVD is the leading cause of death in patients with DMII, with ~ 75% dying from a cardiovascular event, the intersection of DMII and CVD provides a unique therapeutic target. In particular, pulmonary hypertension (PH) related to CVD (Group II PH) may be an optimal target for metformin therapy. The objective of this review article is to provide an overview of the pathophysiology of PH related to left heart disease (PH-LHD), outline the proposed pathophysiologic mechanism of insulin resistance in heart failure and PH-LHD, and evaluate the role metformin may have in heart failure and PH-LHD.

Citing Articles

The Role of Selected Epigenetic Pathways in Cardiovascular Diseases as a Potential Therapeutic Target.

Wolowiec A, Wolowiec L, Grzesk G, Jasniak A, Osiak J, Husejko J Int J Mol Sci. 2023; 24(18).

PMID: 37762023 PMC: 10531432. DOI: 10.3390/ijms241813723.

PGC-1α activity and mitochondrial dysfunction in preterm infants.

Mohammadi A, Higazy R, Gauda E Front Physiol. 2022; 13:997619.

PMID: 36225305 PMC: 9548560. DOI: 10.3389/fphys.2022.997619.

Animal models of pulmonary hypertension due to left heart disease.

Liu S, Yan Y Animal Model Exp Med. 2022; 5(3):197-206.

PMID: 35234367 PMC: 9240728. DOI: 10.1002/ame2.12214.

Senescence Alterations in Pulmonary Hypertension.

Roger I, Milara J, Belhadj N, Cortijo J Cells. 2021; 10(12).

PMID: 34943963 PMC: 8700581. DOI: 10.3390/cells10123456.

References

van Heerebeek L, Somsen A, Paulus W . The failing diabetic heart: focus on diastolic left ventricular dysfunction. Curr Diab Rep. 2009; 9(1):79-86. DOI: 10.1007/s11892-009-0014-9. View

Goncharov D, Goncharova E, Tofovic S, Hu J, Baust J, Pena A . Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018; 198(5):681-684. PMC: 6118018. DOI: 10.1164/rccm.201801-0022LE. View

Willemsen S, Hartog J, Hummel Y, van Ruijven M, van der Horst I, Van Veldhuisen D . Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail. 2010; 13(1):76-82. DOI: 10.1093/eurjhf/hfq168. View

Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D34-41. DOI: 10.1016/j.jacc.2013.10.029. View

Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R . Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001; 37(1):183-8. DOI: 10.1016/s0735-1097(00)01102-5. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Mohan M, Al-Talabany S, McKinnie A, Mordi I, Singh J, Gandy S . A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019; 40(41):3409-3417. PMC: 6823615. DOI: 10.1093/eurheartj/ehz203. View

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Vanderpool R, Saul M, Nouraie M, Gladwin M, Simon M . Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2018; 3(4):298-306. PMC: 5875307. DOI: 10.1001/jamacardio.2018.0128. View

10.

Inoki K, Li Y, Zhu T, Wu J, Guan K . TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9):648-57. DOI: 10.1038/ncb839. View

11.

Assad T, Hemnes A . Metabolic Dysfunction in Pulmonary Arterial Hypertension. Curr Hypertens Rep. 2015; 17(3):20. PMC: 4840894. DOI: 10.1007/s11906-014-0524-y. View

12.

Schiattarella G, Altamirano F, Tong D, French K, Villalobos E, Kim S . Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019; 568(7752):351-356. PMC: 6635957. DOI: 10.1038/s41586-019-1100-z. View

13.

Oh A, Okazaki R, Sam F, Valero-Munoz M . Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. Front Cardiovasc Med. 2019; 6:110. PMC: 6687767. DOI: 10.3389/fcvm.2019.00110. View

14.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

15.

Pieske B, Wachter R . Impact of diabetes and hypertension on the heart. Curr Opin Cardiol. 2008; 23(4):340-9. DOI: 10.1097/HCO.0b013e3283031ab3. View

16.

Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M . Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009; 53(13):1119-26. PMC: 2736110. DOI: 10.1016/j.jacc.2008.11.051. View

17.

Califf R, Adams K, McKenna W, Gheorghiade M, Uretsky B, McNulty S . A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134(1):44-54. DOI: 10.1016/s0002-8703(97)70105-4. View

18.

Lai Y, Tabima D, Dube J, Hughan K, Vanderpool R, Goncharov D . SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Circulation. 2016; 133(8):717-31. PMC: 4766041. DOI: 10.1161/CIRCULATIONAHA.115.018935. View

19.

Zelt J, Chaudhary K, Cadete V, Mielniczuk L, Stewart D . Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. Circ Res. 2019; 124(11):1551-1567. DOI: 10.1161/CIRCRESAHA.118.313650. View

20.

Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D . Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016; 134(1):73-90. PMC: 4930115. DOI: 10.1161/CIRCULATIONAHA.116.021884. View